NEW YORK (TheStreet) -- CHANGE IN RATINGS
upgraded at Jesup & Lamont from Hold to Buy. $63 price target. Stock is trading at an attractive risk/reward ratio.
upgraded at Barclays to Overweight from Equal Weight. Price target jumped to $65 from $57. 2009 and 2010 EPS estimates lowered to $1.20 and $4.40, respectively.
( BEC) upgraded at JP Morgan. Rating raised to Overweight from Neutral. Maintains $75 price target and 2009 EPS estimates of $3.82.
( BUCY) downgraded at Baird from Outperform to Neutral. $10 price target. Company is reliant on slow-growth markets.
( BUCY) target, estimate raised at Barclays. BUCY price target surged to $73 from $64. 2010 EPS estimate increased to $3.55 from $2.90. Maintain Overweight rating.
( BUCY) rated new Outperform at Morgan Stanley. $71 price target. Terex purchase was a positive and should materially add to earnings.
downgraded at Goldman from Buy to Neutral. Valuation call, despite the company's attractive resource upside.
upgraded at BofA/Merrill to Buy from Neutral. Price target set at $45. YRC's market share losses makes valuation increasingly attractive for CNW.
upgraded at Jefferies from Underperform to Hold. $11.50 price target. Company has reduced exposure to gas and trades at an attractive valuation.
upgraded at Jefferies from Underperform to Hold. Valuation call, based on a $1.80 price target.
downgraded at UBS from Buy to Neutral. $16 price target. Estimates also lowered, as sales trends appear to have deteriorated.
( EM) upgraded at Brean Murray from Sell to Hold. Company is likely to exceed conservative earnings expectations.
upgraded at Baird from Neutral to Outperform. $103 price target. Sapien launch should be successful.
downgraded at Credit Suisse to Neutral from Outperform as risk/reward appears balanced. Price target cut by a dollar to $28. 2009 and 2010 EPS estimates set at $1.37 and $1.44, respectively.
downgraded at JP Morgan. Rating lowered to Neutral from Overweight. Eliminates price target. Lowers 2009 EPS estimates to -$1.45 from -$1.42.
upgraded at Baird from Neutral to Outperform. $26 price target. Expect further growth in PC sales trends.
Las Vegas Sands
upgraded at UBS from Neutral to Buy. $20 price target. Expect the company to take market share in a growing Macau market.
( ME) downgraded at JP Morgan. Rating lowered to Neutral from Overweight. Maintains $51 price target and 2009 EPS estimates of $0.74.
upgraded at Credit Suisse to Outperform from Neutral. Anticipating weak 4Q but 2010 should see margins and book value growth, Credit Suisse said. Price target raised to $38 from $32. 2009 EPS sunk to -$1.08, 2010 raised to $3.20.
upgraded at UBS from Neutral to Buy. $37 price target. Investment Banking pipeline is building and management is turning around some areas that have struggled.
rated new Buy at Citigroup. $50 price target. Stock appears under-owned and the company is operating in a sweet spot.
rated new Neutral at Goldman. $33 price target. Company needs to execute better to attract investors.
downgraded at Kaufman from Buy to Hold. $50 price target. Most recent checks suggest work down of handset inventories in Korea.
upgraded at Citigroup from Hold to Buy. Company should benefit from sector rotation. $39 price target.
upgraded at Goldman from Neutral to Buy. Stock also added to the Conviction List, as growth and returns should be strong outside of the price of natural gas.
upgraded at Baird from Neutral to Outperform. $70 price target. See multiple areas for operating leverage, as the environment improves.
downgraded at Oppenheimer from Outperform to Perform. $36 price target. Valuation call, as the company likely has limited upside earnings potential.
upgraded at UBS from Neutral to Buy. $76 price target. Valuation call, as the Macau gaming outlook remains steady.
STOCK COMMENTS / EPS CHANGES
added to Focus List at Kaufman. $6 price target. Channel checks show strong demand across key segments. Buy rating.
target upped at Goldman. Shares of BMY now seen reaching $26. MJN split will boost the company's earnings. Neutral rating.
estimate lower at Credit Suisse. C 2009 EPS to -$0.60 from -$0.05, 2010 set at $0.12. Maintain Neutral rating and $4.50 price target.
estimates cut at Barclays. Barclays lowered CME 2009 and 2010 EPS estimates to $13.25 and $15.68, respectively. Maintain Equal Weight rating and $315 price target.
target boosted at Citigroup Shares of ESRX now seen reaching $112, according to Citigroup. Industry has favorable tailwinds. Buy rating.
estimates, target raised at FBR. Shares of GOOG now seen reaching $810. Estimates also boosted, to reflect channel checks and the latest traffic data. Outperform rating.
estimate cut at Credit Suisse. GS 2009 EPS estimate to $18.08 from $19.30, 2010 set at $17.75. Maintain Outperform rating and $225 price target.
target, estimates cut at Barclays. ICE price target lowered by $3 to $116. 2009 and 2010 EPS estimates reduced to $4.45 and $5.26, respectively. Maintain Overweight rating.
( JOYG) target, estimates raised at Barclays to $67 from $64 on faster recovery. 2010 EPS estimate improved to $3.05, 2011 introduced at $3.95. Reiterate Overweight rating.
price target lowered at Credit Suisse by a dollar to $15. 2009 and 2010 EPS estimates set at $0.70 and $0.03, respectively. Outperform rating.
target increased at Citigroup. MHS target was boosted to $77. Prescription trends remain favorable. Buy rating.
numbers boosted at Citigroup. MRK estimates were increased through 2013. Company should see significant synergies from the SGP deal. Buy rating and new $45 price target.
estimates lower at Barclays.Barclays reduced NYX 2009 and 2010 EPS estimates to $1.94 and $2.28, respectively. Reiterate Overweight rating and $35 price target.
estimates lowered at Goldman through 2011. Company to see higher losses following the recent Clearwire financing. Neutral rating.
estimates, target boosted at Oppenheimer. Shares now seen reaching $17. Estimates also raised, as channel checks show the company has strong order momentum. Outperform rating.
estimates boosted at Goldman through 2011. Centennial acquisition should add to earnings. Buy rating.
price target raised at BofA/Merrill to $40 from $33 as LED cycle remains robust. Reiterate Buy rating.
This article was written by a staff member of TheStreet.com.